References
- Powers AC. Diabetes mellitus. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw-Hill; 2012. p. 2968–3003.
- Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet [Internet]. 2005 Oct;366:1267–78. [cited 2016 Jun 10] Available from: http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(05)67394-1.pdf. doi: 10.1016/S0140-6736(05)67394-1
- Taskinen M, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis [Internet]. 2015 Apr;239:483–95. [cited 2016 Jan 16] Available from: http://www.atherosclerosis-journal.com/article/S0021-9150(15)00088-X/fulltext. doi: 10.1016/j.atherosclerosis.2015.01.039
- Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jul;32:1769–818. [cited 2016 Jan 23]; Available from: http://eurheartj.oxfordjournals.org/content/32/14/1769.long. doi: 10.1093/eurheartj/ehr158
- Bramlage P, Lanzinger S, Rathmann W, et al. Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German DIVE and DPV registries. Diabetes Obes Metab. 2016 Sep;19(1):61–9. [cited 2017 Apr 19] Available from: http://onlinelibrary.wiley.com/doi/10.1111/dom.12783/full. doi: 10.1111/dom.12783
- Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. the framingham study. Am J Med. 1977 May;62:707–14. [cited 2016 Jan 24]; Available from: http://www.sciencedirect.com/science/article/pii/0002934377908749. doi: 10.1016/0002-9343(77)90874-9
- Assmann G, Schulte H, Cullen P, et al. Assessing risk of myocardial infarction and stroke: new data from the Prospective cardiovascular münster (PROCAM) study. Eur J Clin Invest. 2007 Dec;37:925–32. [cited 2017 Apr 28]; Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2362.2007.01888.x/epdf. doi: 10.1111/j.1365-2362.2007.01888.x
- Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007 Jul;115(4):450–8. [cited 2017 Apr 30] Available from: http://circ.ahajournals.org/content/115/4/450. doi: 10.1161/CIRCULATIONAHA.106.637793
- Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 Aug;364(9435):685–96. [cited 2017 Jan 29] Available from: http://0-search.proquest.com.innopac.wits.ac.za/docview/199004507/fulltextPDF/C836D43AB6AC4227PQ/31?accountid=15083. doi: 10.1016/S0140-6736(04)16895-5
- Pérez A, Blanco CG, Hernández-Presa MA, et al. Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. Endocrinol Nutr. 2011 Mar;58:289–90. [cited 2016 Jan 18] Available from: http://www.sciencedirect.com/science/article/pii/S2173509311700617/pdf?md5=e955d90a7e671a70f3c93c571f1a3cb8&pid=1-s2.0-S2173509311700617-main.pdf. doi: 10.1016/j.endonu.2011.03.005
- Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008 Nov;5:319–35. [cited 2017 Jan 29]; Available from: http://journals.sagepub.com/doi/pdf/10.3132/dvdr.2008.046.
- Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004 Jun;27(6):1496–504. [cited 2017 Apr 22] Available from: http://care.diabetesjournals.org/content/27/6/1496.full-text.pdf. doi: 10.2337/diacare.27.6.1496
- Goff Jr DC, Gerstein HC, Ginsberg HN, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol. 2007 Jun;99(12):S21–S33. [cited 2017 Nov 15] Available from: https://doi.org/10.1016/j.amjcard.2007.03.002.
- Goodman SG, Langer A, Bastian NR, et al. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia international study (DYSIS). Can J Cardiol. 2010 Nov;26:330–5. [cited 2016 Jan 17] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989357/. doi: 10.1016/S0828-282X(10)70454-2
- Kennedy AG, MacLean CD, Littenberg B, et al. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care. 2005 May;28(5):1029–34. [cited 2016 Jan 25]; Available from: http://care.diabetesjournals.org/. doi: 10.2337/diacare.28.5.1029
- Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the dyslipidaemia international study. Diabet Med. 2011 Jun;28:1343–51. [cited 2016 Jan 24]Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2011.03360.x/epdf. doi: 10.1111/j.1464-5491.2011.03360.x
- Amod A, Ascott-Evans BH, Berg GI, et al. The 2012 SEMDSA guidelines for the management of type 2 diabetes (revised). JEMDSA. 2012 Aug;17(2):S1–S95. [cited 2016 May 13] Available from: http://www.semdsa.org.za/images/2012_SEMDSA_Guideline_July_FINAL.pdf.
- Zhao S, Wang Y, Mu Y, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia international study (DYSIS). Atherosclerosis. 2014 Aug;235:463–9. [cited 2016 Nov 12]; Available from: https://www.sciencedirect.com/science/article/pii/S0021915014011666. doi: 10.1016/j.atherosclerosis.2014.05.916
- Gitt AK, Jünger C, Smolka W, et al. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol. 2010 Nov;99:723–33. [cited 2016 Jan 23] Available from: http://link.springer.com/article/10.1007%2Fs00392-010-0177-z. doi: 10.1007/s00392-010-0177-z
- Raal F, Schamroth C, Blom D, et al. CEPHEUS SA: a South African survey on the under-treatment of hypercholesterolaemia. Cardiovasc J Afr. 2011 Oct;22(5):234–40. [cited 2019 Oct 15]; Available from: https://0-www-ncbi-nlm-nih-gov.innopac.wits.ac.za/pmc/articles/PMC3721857/. doi: 10.5830/CVJA-2011-044
- Blom DJ, Raal F, Amod A, et al. Management of low-density lipoprotein cholesterol levels in South Africa: the international ChoLesterol management Practice study (ICLPS). Cardiovasc J Afr. 2019 Jan;30(1):15–23. [cited 2019 Oct 15]; Available from: http://0-resolver.ebscohost.com.innopac.wits.ac.za/openurl?sid=Entrez%3aPubMed&id=pmid%3a30720848&site=ftf-live. doi: 10.5830/CVJA-2018-054
- Raal FJ, Blom D, Naidoo S, et al. Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia international study (DYSIS). Cardiovasc J Afr. 2013 Sep;24(8):330–8. [cited 2019 Oct 15] Available from: https://0-www-ncbi-nlm-nih-gov.innopac.wits.ac.za/pmc/articles/PMC3821092/pdf/cvja-24-330.pdf. doi: 10.5830/CVJA-2013-071
- Mahato RV, Gyawali P, Raut PP, et al. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: glycated haemoglobin as a dual biomarker. Biomed Res. 2011 Mar;22(3):375–80. [cited 2017 Apr 22]; Available from: http://www.alliedacademies.org/articles/association-between-glycaemic-control-and-serum-lipid-profile-in-type-2-diabetic-patients-glycated-haemoglobin-as-a-dual-biomarker.pdf.
- Chew BH, Ismail M, Lee PY, et al. Determinants of uncontrolled dyslipidaemia among adult type 2 diabetes in Malaysia: the Malaysian diabetes registry 2009. Diabetes Res Clin Pract. 2012 Jun;96:339–47. [cited 2016 Jan 27] Available from: http://0-www.sciencedirect.com.innopac.wits.ac.za/science/article/pii/S0168822712000393. doi: 10.1016/j.diabres.2012.01.017